10,11-Seco-LSD

10,11-Seco-LSD
Clinical data
Other names"[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide
Drug classPartial ergoline
ATC code
  • None
Identifiers
CAS Number
Chemical and physical data
3D model (JSmol)
  • O=C([C@@]1C=C[C@@]([H])(CC2=CN([H])C3=CC=CC=C23)N(C)C1)N(CC)CC
  • InChI=1S/C20H26N3O/c1-4-23(5-2)20(24)15-10-11-17(22(3)14-15)12-16-13-21-19-9-7-6-8-18(16)19/h6-11,13,17,21H,4-5,12,14H2,1-3H3/t17-/m0/s1
  • Key:CGFPZODXTFFRAH-KRWDZBQOSA-N

10,11-Seco-LSD is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).[1] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.[1] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.[1] Its pharmacology was not described.[1]

See also

References

  1. ^ a b c d WO 2021076572, Olson DE, Dunlap LM, Wagner F, Chytil M, Powell NE, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California 



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.